Paricalcitol: A review of its use in the management of secondary hyperparathyroidism

Drugs

Volumn 65, Issue 4, 2005, Pages 559-576

  Robinson, Dean M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; RETINOID X RECEPTOR; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; BILIARY EXCRETION; BONE DEMINERALIZATION; BONE METABOLISM; BONE TURNOVER; CALCIUM TRANSPORT; CELL MATURATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EDEMA; GENE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; LONG TERM CARE; NAUSEA; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TRANSCRIPTION REGULATION; VITAMIN D RESPONSIVE GENE; VOMITING;

CLINICAL TRIALS; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC;

EID: 16344366184     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565040-00008     Document Type: Review

References (79)

1. Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004 May; 19 (5): 1174-81
2. U.S. Renal Data System. 2004 annual data report: atlas of end-stage renal disease in the United States [online]. Available from URL: http://www.usrds. org/ [Accessed 2004 Sep 9]
3. Stein MS, Wark JD. An update on the therapeutic potential of vitamin D analogues. Expert Opin Invest Drugs 2003; 12 (5): 825-40
4. Brown AJ, Coyne DW. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol 2002; 1 (5): 313-27
5. Brown AJ. Vitamin D analogues. Am J Kidney Dis 1998 Oct; 32 (4 Suppl. 2 Suppl. 2): 25-39
6. Cunningham J. What is the optimal regimen for vitamin D? Kidney Int Suppl 1999 Dec; 56 Suppl. 73: S59-64
7. Martin KJ, Gonzalez EA. Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001 Dec; 38 (6): 1430-6
8. Schroeder NJ, Cunningham J. What's new in vitamin D for the nephrologist? Nephrol Dial Transplant 2000; 15 (4): 460-6
9. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative [online]. Available from URL: http://www.kidney.org/professionals/kdoqi [Accessed 2004 Sep 30]
10. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 May 18; 342 (20): 1478-83
11. Norris KC. Avoiding the risks of secondary hyperparathyroidism in chronic renal failure: A new approach, and a review. Dial Transplant 2001; 30 (6): 355-67
12. Salusky IB, Goodman WG. Managing phosphate retention: is a change necessary? Nephrol Dial Transplant 2000; 15 (11); 1738-42
13. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001 Oct; 12 (10): 2131-8
14. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 Aug; 15 (8): 2208-18
15. Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Paediatr Drugs 2003; 5 (11): 763-76
16. Carbajo E, Lopez JM, Santos F, et al. Histologic and dynamic changes induced by chronic metabolic acidosis in the rat growth plate. J Am Soc Nephrol 2001 Jun; 12 (6): 1228-34
17. Thadhani R, Wolf M, Ofsthun N, et al. Hemodialysis survival and vitamin D injections: a historical cohort study [abstract no. F-PO553]. Proceedings of the American Society of Nephrology; 2004 Oct 27-Nov 1; St Louis
18. Graul A, Leeson PA, Castaner J. Paricalcitol: vitamin D analog, treatment for hyperparathyroidism. Drugs Future 1998; 23 (6): 602-6
19. Abbott Laboratories. Zemplar® paricalcitol injection [online]. Available from URL: http://www.fda.gov [Accessed 2004 Sep 29]
20. Dusso AS, Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol 2004; 24 (1): 10-6
21. Schroeder NJ, Burrin JM, Noonan K, et al. Effects of 'non-calcaemic' vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells. Nephron Physiol 2003; 94 (4): 62-73
22. Tocchini-Valentini G, Rochel N, Wurtz JM, et al. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc Natl Acad Sci U S A 2001 May 8; 98 (10): 5491-6
23. Adams JS, Chen H, Chun R, et al. Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism. J Steroid Biochem Mol Biol 2004 May; 89-90 (1-5): 461-5
24. Leong GM, Subramaniam N, Issa LL, et al. Ski-interacting protein, a bifunctional nuclear receptor coregulator that interacts with N-CoR/SMRT and p300. Biochem Biophys Res Commun 2004 Mar 19; 315 (4): 1070-6
25. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995 Nov; 26 (5): 852-60
26. 2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 2003 Jun; 63 (6): 2020-7
27. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997 Jul; 30 (1): 105-12
28. WAF1 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001 Dec; 60 (6): 2109-17
29. 2 on calcium and phosphorus in normal and uremic rats. Kidney Int 2002 Oct; 62 (4): 1277-84
30. 3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002 May; 139 (5): 279-84
31. 2 decreases with duration of treatment. J Am Soc Nephrol 2000 Nov; 11 (11): 2088-94
32. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 2000 Oct; 36 (4): 789-96
33. 2, a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol 2000 Oct; 11 (10): 1857-64
34. 2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999 May; 10 (5): 980-5
35. Zager RA. Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. Am J Pathol 1999 Jun; 154 (6): 1899-909
36. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004 Apr 16; 279 (16): 16754-66
37. Nakane M, Fey TA, Dixon DB. Effect of vitamin D receptor activators on bone formation and resorption [abstract no. SA PO611 plus poster]. Proceedings of the American Society of Nephrology; 2004 Oct 27-Nov 1; St Louis
38. 2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 2001 Jul; 12 (7): 1468-74
39. 2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br J Dermatol 2004 Jul; 151 (1): 190-5
40. 2 in humans [abstract no. S402]. J Bone Miner Res 1997; 12 Suppl.: S453
41. Lutwak L. Medical Officer's review. Paricalcitol injection [online]. Available from URL: http://www.fda.gov/cder/foi/nda/98/20819_Zemplar.htm [Accessed 2004 Sep 20]
42. 2. Am J Kidney Dis 1998 Oct; 32 (4 Suppl. 2 Suppl. 2): 55-60
43. 2) in healthy subjects [abstract no. p428]. Nephrology (Carlton) 1997 May; 3 Suppl. 1: S182
44. Cato A, Buschen C, Ahmed A, et al. The pharmacokinetics of paracalcin [abstract no. PIII-95]. 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5-8; San Diego, 218
45. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003 Apr; 63 (4): 1483-90
46. 2. Am J Kidney Dis 1998 Oct; 32 (4 Suppl. 2): S48-54
47. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998 Aug; 9 (8): 1427-32
48. Elashof B, Lutwak L. Statistical review. Capthrol (tradename) paricalcin injection/paricalcitol injection (generic name) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/98/20819_Zemplar.htm [Accessed 2004 Sep 20]
49. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31; 349: 446-56
50. Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001 Oct; 56 (4): 315-23
51. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001 Nov; 38 (5 Suppl. 5): S45-50
52. 2. Am J Kidney Dis 1998 Oct; 32 (4 Suppl. 2 Suppl. 2): S61-6
53. Mittman N, Khanna, R., Rani S, et al. Comparison of paricalcitol and calcitriol therapy for the treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis [abstract no. PUB253]. Proceedings of the American Society of Nephrology; 2004 Oct 27-Nov 1; St Louis
54. Melnick JZ, Kommala D, Mattingly S, et al. Paricalcitol and calcitriol in treating SHPT in children-a comparison of 2 studies [abstract no. SU-P0930]. Proceedings of the American Society of Nephrology; 2004 Oct 27-Nov 1; St Louis
55. Zemplar. Clinical review: executive summary. Summaries of medical and clinical pharmacology reviews of pediatric studies [online]. Available from URL: http://www.fda.gov/cder/foi/esum/2004/20819se5-014_zemplar_clinical_bpca.pdf [Accessed 2004 Sep 15]
56. Colussi G. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis [letter]. N Engl J Med 2003 Nov 13; 349 (20): 1971-2; author reply 1971-2
57. Llach F. Paricalcitol: an updated review and guidelines for use. Dial Transplant 2001; 30 (10): 654-64
58. Martin KJ, Gonzalez E, Lindberg JS, et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 2001 Nov; 38 (5 Suppl. 5): S57-63
59. Agencia Espanola del Medicamento. Resolucion de autorizacion de comercializacion de la especialidad farmaceutica "Zemplar 5 g/mL solucion inyectable". Madrid: Minsterio de Sanidad y Consumo, 2002 Aug
60. Medicine and Healthcare products Regulatory Agency. Grant of marketing authorisation. Zemplar 5 microgram/ml solution for injection. London: Department of Health, 2003 Jul
61. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35 (6): 1226-37
62. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values [published erratum appears in N Engl J Med 1999 Apr 22; 340 (16): 1300]. N Engl J Med 1998 Oct 8; 339 (15): 1063-72
63. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values [published erratum appears in N Engl J Med 1999 Apr 22; 340 (16): 1300]. N Engl J Med 1998 Oct 8; 339 (15): 1063-72
64. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23 (6): 369-79
65. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995 Jul 20; 333 (3): 166-74
66. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 Sep; 92 (3): 1436-43
67. Wang M, Herez G, Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995 Nov; 26 (5): 836-44
68. Brancaccio D, Cozzolino M, Gorio A, et al. Bone disease in uremic patients: advances in PTH suppression. J Nephrol 2002 Nov-Dec; 15 Suppl. 6: S86-93
69. Llach F, Fernandez E. Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int 2003; 64 Suppl. 87: S113-9
70. Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984 Jun; 73 (6): 1580-9
71. Malluche HH, Monier-Faugere MC. Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol 1999; 52 (5): 267-77
72. Amgen. European Commission approves innovative first-in-class treatment for a serious complication of chronic kidney disease [online]. Available from URL: http://www.amgen.com/news/viewPR.jsp?id=637355 [Accessed 2004 Nov 22]
73. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 2004 Nov; 38 (11): 1871-80
74. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003 Mar; 14 (3): 575-83
75. Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs 2005; 65 (2): 271-81
76. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001 Mar; 37 (3): 532-43
77. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004 May; 43 (5): 877-90
78. Acharya M, Andress D, Lunde N. Safety experience of paricalcitol (Zemplar®) capsule in phase 3 trials in CKD stages 3 and 4 patients with secondary hyperparathyroidism (SHPT) [abstract no. SA PO935 plus poster]. Proceedings of the American Society of Nephrology; 2004 Oct 27-Nov 1; St Louis
79. Abbott Laboratories. Abbott laboratories submits new drug application to U.S. FDA for Zemplar® (Paricalcitol) capsules [online]. Available from URL: http://abbott.com/news/press_release.cfm?id=802 [Accessed 2005 Feb 1]